Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 121
of 7Next
1:
Related Articles, Links
Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ.
Free in PMC
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
J Transl Med. 2007 Jul 2;5:32.
PMID: 17605814 [PubMed]
2:
Related Articles, Links
Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ.
Abstract
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
J Clin Oncol. 2008 Aug 1;26(22):3743-8.
PMID: 18669461 [PubMed - indexed for MEDLINE]
3:
Related Articles, Links
Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, Shalinsky DR, Demetri GD, Heymach JV.
Free Full Text
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Clin Cancer Res. 2007 May 1;13(9):2643-50.
PMID: 17473195 [PubMed - indexed for MEDLINE]
4:
Related Articles, Links
Le Tourneau C, Raymond E, Faivre S.
Free in PMC
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST).
Ther Clin Risk Manag. 2007 Jun;3(2):341-8.
PMID: 18360643 [PubMed - in process]
5:
Related Articles, Links
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI.
Abstract
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 2006 Jan 1;24(1):16-24. Epub 2005 Dec 5.
PMID: 16330672 [PubMed - indexed for MEDLINE]
6:
Related Articles, Links
Denduluri N, Yang SX, Berman AW, Nguyen D, Liewehr DJ, Steinberg SM, Swain SM.
Abstract
Circulating biomarkers of bevacizumab activity in patients with breast cancer.
Cancer Biol Ther. 2008 Jan;7(1):15-20. Epub 2007 Nov 21.
PMID: 18059178 [PubMed - indexed for MEDLINE]
7:
Related Articles, Links
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD.
Free Full Text
Sunitinib in patients with metastatic renal cell carcinoma.
JAMA. 2006 Jun 7;295(21):2516-24.
PMID: 16757724 [PubMed - indexed for MEDLINE]
8:
Related Articles, Links
Adams VR, Leggas M.
Abstract
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Clin Ther. 2007 Jul;29(7):1338-53. Review.
PMID: 17825686 [PubMed - indexed for MEDLINE]
9:
Related Articles, Links
Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R.
Free Full Text
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Clin Cancer Res. 2007 Mar 1;13(5):1367-73. Review.
PMID: 17332278 [PubMed - indexed for MEDLINE]
10:
Related Articles, Links
Sosman JA, Puzanov I, Atkins MB.
Free Full Text
Opportunities and obstacles to combination targeted therapy in renal cell cancer.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):764s-769s. Review.
PMID: 17255307 [PubMed - indexed for MEDLINE]
11:
Related Articles, Links
Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS.
Free in PMC
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17069-74. Epub 2007 Oct 17.
PMID: 17942672 [PubMed - indexed for MEDLINE]
12:
Related Articles, Links
Deeks ED, Keating GM.
Abstract
Sunitinib.
Drugs. 2006;66(17):2255-66; discussion 2267-8. Review.
PMID: 17137406 [PubMed - indexed for MEDLINE]
13:
Related Articles, Links
Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M, Marmé D.
Free Full Text
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
Ann Oncol. 2005 Apr;16(4):558-65. Epub 2005 Feb 10.
PMID: 15705616 [PubMed - indexed for MEDLINE]
14:
Related Articles, Links
Zaman K, Driscoll R, Hahn D, Werffeli P, Goodman SL, Bauer J, Leyvraz S, Lejeune F, Stupp R, Rüegg C.
Abstract
Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
Int J Cancer. 2006 Feb 1;118(3):755-64.
PMID: 16114015 [PubMed - indexed for MEDLINE]
15:
Related Articles, Links
Grandinetti CA, Goldspiel BR.
Abstract
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Pharmacotherapy. 2007 Aug;27(8):1125-44. Review.
PMID: 17655513 [PubMed - indexed for MEDLINE]
16:
Related Articles, Links
Chouhan JD, Zamarripa DE, Lai PH, Oramasionwu CU, Grabinski JL.
Abstract
Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
J Oncol Pharm Pract. 2007 Mar;13(1):5-15. Review.
PMID: 17621562 [PubMed - indexed for MEDLINE]
17:
Related Articles, Links
Yilmaztepe A, Ulukaya E, Zik B, Yagci A, Sevimli A, Yilmaz M, Erdogan BB, Koc M, Akgoz S, Karadag M, Tokullugil A.
Abstract
Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: a pilot study.
Cancer Invest. 2007 Aug;25(5):322-7.
PMID: 17661207 [PubMed - indexed for MEDLINE]
18:
Related Articles, Links
Radulovic S, Bjelogrlic SK.
Abstract
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.
PMID: 17935273 [PubMed - indexed for MEDLINE]
19:
Related Articles, Links
Schöffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H.
Free Full Text
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.
Ann Oncol. 2006 Aug;17(8):1185-96. Epub 2006 Jan 17. Review.
PMID: 16418310 [PubMed - indexed for MEDLINE]
20:
Related Articles, Links
Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE, Evering W.
Abstract
Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors.
Toxicol Pathol. 2008 Nov 3. [Epub ahead of print]
PMID: 18981453 [PubMed - as supplied by publisher]
Items 1 - 20 of 121
of 7Next